Vildagliptin ameliorates intrapulmonary vasodilatation and angiogenesis in chronic common bile duct ligationinduced hepatopulmonary syndrome in rat

Faculty of Medicine

Assiut University

Vildagliptin ameliorates intrapulmonary vasodilatation and angiogenesis in chronic common bile duct ligationinduced hepatopulmonary syndrome in rat

Research Authors
Safwat A Mangoura, Marwa A Ahmed, Nashwa Hamad, Andrew Z Zaka, Khaled A Khalaf, Mohamed Abdelhakim Mahdy
Research Date
Research Department
Department of Gastroenterology and Tropical Medicine
Research Member
Khaled Abu bakr Khalaf
Research Website
https://www.sciencedirect.com/science/article/pii/S2210740124001293/pdfft?crasolve=1&r=8e3f3a302efa0da3&ts=1731841333987&rtype=https&vrr=UKN&redir=UKN&redir_fr=UKN&redir_arc=UKN&vhash=UKN&host=d3d3LnNjaWVuY2VkaXJlY3QuY29t&tsoh=d3d3LnNjaWVuY2VkaXJlY3QuY29t
Research Year
2024
Research Abstract

Experimental hepatopulmonary syndrome (HPS) is best reproduced in the rat common bile duct ligation (CBDL) model. Vildagliptin (Vild) is an anti-hyperglycemic drug that exerts beneficial anti-inflammatory, anti-oxidant and anti-fibrotic effects. Therefore, the present search aimed to explore the possible effectiveness of Vild in CBDL-induced HPS model.